StreetAlpha.app
Home › Stocks › DMAC

DiaMedica Therapeutics Inc. (DMAC)

$8.25
▲ +2.87%
LAST CLOSE · NOV 20

DiaMedica Therapeutics develops DM199, an experimental protein therapy for preeclampsia, fetal growth restriction and acute ischemic stroke. It last closed at $8.25 on Nov 20, up 2.87% on the day. The next earnings report for DMAC is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, DMAC reported EPS of -$0.21. Over its last 8 reports the stock moved an average of 6.7% the session after earnings. Over the last 12 months DMAC insiders bought $7.6M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is DMAC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DMAC.

Key Stats

Last 12 months
Results
Net income
−$40.2M
EPS (diluted)
−$0.75
Free cash flow
−$33.8M
Valuation
Market cap
$445.1M
54.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.8M
At Sep 30
Shareholder equity
$28.7M
Shares outstanding
54.0M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$13.6M−$13.6MFY2021FY2022: −$13.7M−$13.7MFY2022FY2023: −$19.4M−$19.4MFY2023FY2024: −$24.4M−$24.4MFY2024FY2025: −$32.8M−$32.8MFY2025

From DMAC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · After the close
Reported EPS
-$0.21
Quarter ended Sep 2026
Year ago EPS
-$0.17
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.18Dec '24Mar 2025: -$0.18Mar '25Jun 2025: -$0.18Jun '25Sep 2025: -$0.17Sep '25Dec 2025: -$0.17Dec '25Mar 2026: -$0.19Mar '26Jun 2026: -$0.19Jun '26Sep 2026: -$0.21Sep '26Latest -$0.21
Revenue by quarter
Not enough quarters on file yet.
How DMAC moved after its last 8 reports
Average move the session after a report ±6.7%
Nov 12, 2026After the close−5.8%
Aug 10, 2026After the close+3.3%
May 6, 2026After the close+0.1%
Mar 30, 2026After the close+2.0%
Nov 12, 2025After the close−14.1%
Aug 12, 2025After the close+14.9%
May 13, 2025After the close+0.5%
Mar 17, 2025After the close−13.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DMACStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DMAC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DMAC

Technical Analysis

DMAC · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 11% below its 20 day and 2% below its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the Pivot at $8.17, and the nearest resistance the 50 day average at $8.38.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.4%/day
Key levels
$11.0052 week high+33.3%
$9.1620 day average+11.0%
$8.53Swing high (Jul 6)+3.4%
$8.47Pivot R1+2.7%
$8.3850 day average+1.6%
$8.25Last close
$8.17Pivot−1.0%
$7.96Pivot S1−3.5%
$7.66Swing low (Oct 8)−7.2%
$7.62100 day average−7.6%
$7.18200 day average−13.0%
$5.2552 week low−36.4%
Indicators
RSI (14)44.37Middle of its rangeNeutral
MACD-0.02Below its signal lineBearish
Stochastic12.7Near the bottom of its rangeOversold
ADX (14)24.3Weak trend
Williams %R-88.1Oversold below −80, overbought above −20Oversold
CCI (20)-125.1Oversold below −100, overbought above 100Oversold
Rate of change−11.9%Change over 10 sessionsBearish
ATR (14)$0.70Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for DMAC

What happened before

See how DMAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DMAC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DMAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DMACHow many large options trades hit DMAC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

DMAC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 26 selling
  • ▲Held by funds +0.5 pts
  • ▲Funds holding +7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9790+7.8%
In funds' top 1000–
Held by funds23.8%23.2%+0.5 pts
New / increased15 / 3811 / 32+23.3%
Reduced / sold out19 / 720 / 18−31.6%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DMAC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DMAC Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$7.6M1 buy · 1 insider
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 25, 2025Ab Trill10% ownerBuy1,061,277$7.19$7.6M
Aug 27, 2025Jan Stahlberg10% ownerBuy1,000,000$5.96$6.0M
Jul 23, 2025Koch Thomas Von10% ownerBuy2,857,142$3.50$10.0M
Jul 23, 2025Jan Stahlberg10% ownerBuy1,542,857$3.50$5.4M
Jul 23, 2025Richard Jacinto II10% ownerBuy400,000$3.50$1.4M
Every insider buy and sale for DMAC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DMAC insider trades →

From SEC Form 4 filings by DMAC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMAC is in one of them and how their past DMAC trades turned out.

DMAC in the AI portfolios
Loading…

DMAC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DMAC in an article yet. Here's the latest on the wider market.

DMAC in the news

About DiaMedica Therapeutics

DiaMedica Therapeutics is a biopharmaceutical company based in Minneapolis, Minnesota. It is developing DM199, a recombinant form of the human tissue kallikrein-1 protein, as a possible treatment for preeclampsia, fetal growth restriction and acute ischemic stroke. The drug is still in clinical trials and is not yet approved for sale. The company is also working on DM300, a recombinant ulinastatin, as a possible treatment for severe acute pancreatitis.

Headquarters
Minneapolis, MN